SCHEMBL1868892

SCHEMBL1868892

CCCS(=O)(=O)Nc1ccc(F)c(C(=O)OC)c1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
BRAF P15056 19/20 0.57
BMPR1B O00238 1/20 0.52
PLK4 O00444 1/20 0.52
PIR O00625 1/20 0.52
AURKA O14965 1/20 0.52
DCLK1 O15075 1/20 0.52
EPHB6 O15197 1/20 0.52
RIPK2 O43353 1/20 0.52
STK16 O75716 1/20 0.52
OXSR1 O95747 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
RAF1 P04049 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
FES P07332 1/20 0.52
CSF1R P07333 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20408784 0.92 BRAF (0.54) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL28740528 0.90 BRAF (0.49) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL16066858 0.90 BRAF (0.57) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL23098882 0.90 CYP2C19 (0.56) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL1461847 0.87 BRAF (0.54) CYP3A4CYP2C9CYP2C19BRAF
SCHEMBL1436965 0.87 BRAF (0.54) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL1438201 0.87 BRAF (0.55) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL8240987 0.86 CYP3A4 (0.53) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL855654 0.86 CYP3A4 (0.62) CYP3A4CYP2C9CYP2C19BRAFBMPR1B
SCHEMBL413368 0.86 CYP3A4 (0.62) CYP3A4CYP2C9CYP2C19BRAFBMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858927-B2 Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-01-02 US disclosed
US-11040027-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2021-06-22 US disclosed
US-20210078995-A1 PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2021-03-18 US disclosed
EP-2780341-B1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2019-02-13 EP disclosed
EP-2780341-B1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2019-02-13 EP disclosed
WO-2018134254-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2018-07-26 WO disclosed
US-9550781-B2 Kinase modulating compounds, compositions containing the same and use thereof CENTAURUS BIOPHARMA CO., LTD. (CN) 2017-01-24 US disclosed
US-9550781-B2 Kinase modulating compounds, compositions containing the same and use thereof CENTAURUS BIOPHARMA CO., LTD. (CN) 2017-01-24 US disclosed
US-9550781-B2 Kinase modulating compounds, compositions containing the same and use thereof CENTAURUS BIOPHARMA CO., LTD. (CN) 2017-01-24 US disclosed
US-20140296261-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CENTAURUS BIOPHARMA CO., LTD. (CN) 2014-10-02 US disclosed
US-20140296261-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CENTAURUS BIOPHARMA CO., LTD. (CN) 2014-10-02 US disclosed
US-20140296261-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CENTAURUS BIOPHARMA CO., LTD. (CN) 2014-10-02 US disclosed
EP-2780341-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF Centaurus Biopharma Co., Ltd. (CN) 2014-09-24 EP disclosed
WO-2013071865-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CENTAURUS BIOPHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
WO-2013071865-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF CENTAURUS BIOPHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
EP-2498608-A1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS GlaxoSmithKline LLC (US) 2012-09-19 EP disclosed
WO-2011059610-A1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040027-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, HNF4A, HGF CYP3A4 1499/4885CYP2C9 3983/4885CYP2C19 4554/4885
US-20140296261-A1 KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF MAP3K20, MAP3K1, PRKCH CYP3A4 4707/4885CYP2C9 4834/4885CYP2C19 4619/4885
US-20210078995-A1 PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH MAPK4, MAP3K4, MAP4K1 CYP3A4 971/4885CYP2C9 2756/4885CYP2C19 4255/4885
US-11858927-B2 Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAP3K4, MAP4K1 CYP3A4 971/4885CYP2C9 2756/4885CYP2C19 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.